Toby Sykes co-leads our Pharmaceuticals Growth Equity practice. He has over 15 years of experience in both corporate finance and the pharmaceuticals industry. Toby joined the London office of Essex Woodlands in 2007, was promoted to Partner in 2013, and was promoted to Managing Director in June 2015. He led Essex’s growth equity investment in Healthcare Brands International, which was sold to Meda AB in 2011, and manages Essex Woodlands’ growth equity investments in MedAvante and Biotoscana.
Prior to Essex Woodlands, Toby was Director of Business Development at Cephalon Inc, where he helped the company build its European business through a transformational acquisition. Prior to Cephalon, Toby worked in corporate finance for Arthur Andersen and Deloitte, and advised on a number of growth equity and buyout transactions in the life sciences industry.
Toby serves on the Board of Directors at EUSA Pharma (UK) Ltd., Biotoscana and Chroma Therapeutics. Toby holds a Bachelor of Arts degree from Oxford University and a Doctor of Philosophy degree in Molecular Biology from King’s College London. He has a keen interest in rugby, cricket, golf, sailing and natural history.